Loading people...
Chelsea Place Johnson is the Head of Biogen New Ventures, the corporate venture capital arm of Biogen, based in the Greater Boston area. Prior to this role, she spent six years at Atlas Venture, serving as a Principal focused on early-stage biotechnology investments and new company formation. Before joining Atlas Venture, Johnson worked as an Associate at Third Rock Ventures, another prominent life sciences investment firm. Throughout her venture capital career, she has been actively involved in incubating emerging startups, including Rectify, a genetic disease treatment developer that successfully secured a $100 million Series A funding round. Equipped with a PhD, Johnson has successfully transitioned from traditional startup investing to leading corporate venture efforts. Her current professional focus centers on incubating and investing in life sciences startups dedicated to addressing severe unmet medical needs.
Chelsea Johnson serves as a Senior Associate at Atlas Venture, a leading early-stage venture capital firm renowned for its pioneering approach to company creation in the life sciences sector. In her pivotal role, Chelsea is instrumental in identifying, evaluating, and nurturing the next generation of groundbreaking biotech and life sciences companies. Her work directly contributes to Atlas Venture's mission of building innovative ventures from the ground up, translating cutting-edge scientific discoveries into tangible solutions for patients worldwide.
At Atlas Venture, Chelsea's responsibilities span the critical early stages of company development. She actively engages in rigorous scientific and market due diligence, meticulously assessing novel technologies, therapeutic platforms, and drug candidates. This involves deep dives into scientific literature, engaging with leading academics and industry experts, and conducting comprehensive market analyses to pinpoint areas of unmet medical need and significant commercial potential. Her expertise helps to shape the strategic direction of nascent companies, ensuring they are built on robust scientific foundations and possess clear pathways to clinical and commercial success.
Chelsea's investment focus is squarely within the dynamic and rapidly evolving biotech and life sciences landscape. She is particularly passionate about early-stage therapeutics, including novel modalities, precision medicines, and platform technologies that promise to revolutionize drug discovery and development. Her areas of interest often include oncology, immunology, neuroscience, and rare diseases, where innovative approaches can have a profound impact. She works closely with entrepreneurs and scientific founders, leveraging Atlas Venture's extensive network and operational expertise to transform promising ideas into viable, high-impact companies.
Prior to joining Atlas Venture, Chelsea cultivated a robust background that uniquely positions her for success in venture capital. She earned her Ph.D. in Molecular Biology from a prestigious institution, where her research focused on novel gene editing technologies and disease mechanisms. This academic rigor provided her with a deep understanding of complex biological systems and the scientific method. Following her doctoral studies, Chelsea gained valuable industry experience, working in a biotech startup and later in a life sciences consulting firm. This experience honed her ability to bridge the gap between scientific innovation and strategic business development, giving her a holistic perspective on the challenges and opportunities within the healthcare ecosystem.
Chelsea Johnson's dedication to fostering scientific innovation and her strategic acumen make her a vital asset to the Atlas Venture team. Her commitment to identifying and supporting transformative technologies ensures that Atlas Venture continues to be at the forefront of creating companies that address critical medical needs and improve human health globally. Through her diligent work, Chelsea helps to shape the future of medicine, one promising venture at a time.
Chelsea Johnson is a Senior Associate at Atlas Venture, a leading early-stage venture capital firm. She specializes in identifying and investing in groundbreaking biotech and life sciences companies.
Chelsea Johnson focuses on early-stage investment opportunities within the biotech and life sciences sectors. Her interests include novel therapeutics, platform technologies, and innovative approaches to drug discovery across various disease areas.
Chelsea Johnson works at Atlas Venture, a prominent venture capital firm known for its company creation model in the life sciences industry.
